


CLAIMS

1. Use of (a) a therapeutically effective amount of a pharmaceutical composition, and (b) a pharmaceutically acceptable excipient, carrier, or diluent in the manufacture of a medicament for the treatment of a condition selected from the group consisting of obesity and the metabolic syndrome in a mammal including a human, wherein the medicament is to be administered to a mammalian subject in need thereof,

the pharmaceutical composition comprises a compound of Formula (VII-e):



or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, or solvate that is effective in the treatment or prevention of a condition selected from the group consisting of obesity and the metabolic syndrome in a mammal including a human, and wherein the symbols have the following meanings and are, for each occurrence, independently selected:

Z is a carbon or N;

Q-2 is heterocycle containing at least one heteroatom selected from N, O and S, or aryl;

Q-1 is aromatic ring containing at least one heteroatom selected from N, O and S or phenyl;

R₁ is hydrogen;

R₃ is hydrogen;

R₄, and R₇ are hydrogen;

R₆ is absent or hydrogen;

R₂', R₂'', R₂''' and R₂''' are each independently absent, hydrogen, cyano, nitro, trihalomethyl, OCF₃, alkyl or substituted alkyl, heterocycle containing

at least one heteroatom selected from N, O and S, or substituted heterocycle containing at least one heteroatom selected from N, O and S, or OR_a , NR_bR_c , $C(=O)OR_e$, $C(=O)R_a$, $C(=O)NR_bR_c$, $OC(=O)R_a$, or $NR_bC(=O)R_a$,






$R_{5'}$, $R_{5''}$ and $R_{5'''}$ are each independently hydrogen, halogen, cyano, nitro, CF_3 , OCF_3 , alkyl or substituted alkyl, OR_a , SR_a , $C(=O)R_a$, $C(=O)OR_a$, NH_2 , $S(O)_2NH_2$, NR_bR_c , heterocycle containing at least one heteroatom selected from N, O and S, or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl;


R_a is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S, or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl;

R_b and R_c are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S, or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl, or said R_b and R_c together with the N to which they are bonded optionally form a heterocycle containing at least one heteroatom selected from N, O and S or substituted heterocycle containing at least one heteroatom selected from N, O and S; and


R_e is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl.

2. The use of claim 1, wherein the compound of Formula (VII-e) is a compound selected from the group consisting of Formula (VII-g), Formula (VII-f), Formula (VII-h), Formula (VII-m), Formula (VII-n) and Formula (VII-o):





3. Use of (a) a therapeutically effective amount of a pharmaceutical composition, and
 (b) a pharmaceutically acceptable excipient, carrier, or diluent in the manufacture of a
 medicament for the treatment of a condition selected from the group consisting of
 obesity and the metabolic syndrome in a mammal including a human, wherein the
 medicament is to be administered to a mammalian subject in need thereof,
 the pharmaceutical composition comprises a compound of Formula II:



or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt,
 or solvate that is effective in the treatment or prevention of a condition
 selected from the group consisting of obesity and the metabolic
 syndrome in a mammal including a human, and
 wherein the symbols have the following meanings and are, for each occurrence,
 independently selected:
 Het is a 5- or 6-membered aromatic ring containing at least one heteroatom
 selected from N, O and S; R₁ is hydrogen;
 R₄, R₇, and R₈ are hydrogen;

R₃ is hydrogen=;

R₆ and R₉ are each independently hydrogen, halogen, cyano, nitro, CF₃, OCF₃, alkyl or substituted alkyl, or OR_a;

R₁₀ is hydrogen, or alkyl or substituted alkyl;


R₁₄ and R₁₅ are independently hydrogen, alkyl or substituted alkyl, or said R₁₄ and R₁₅ together with the N to which they are bonded optionally form a heterocycle containing at least one heteroatom selected from N, O and S or substituted heterocycle containing at least one heteroatom selected from N, O and S.

R_a is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S, or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl;

R_b and R_c are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S, or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl, or said R_b and R_c together with the N to which they are bonded optionally form a heterocycle containing at least one heteroatom selected from N, O and S or substituted heterocycle containing at least one heteroatom selected from N, O and S; and

R_e is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl.

4. The use of claim 3, wherein the compound of Formula II is a compound of Formula III:




or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, or solvate that is effective in the treatment or prevention of a condition selected from the group consisting of obesity and the metabolic syndrome thereof in a mammal including a human, and wherein the symbols have the following meanings and are, for each occurrence, independently selected:

R_{11} is hydrogen or C_{1-4} alkyl;

R_{12} and R_{13} are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl, or said R_{12} and R_{13} together with the N to which they are bonded optionally form a heterocycle containing at least one heteroatom selected from N, O and S or substituted heterocycle containing at least one heteroatom selected from N, O and S;


n is an integer selected from 2, 3, 4, 5 or 6.

5. The use of claim 3, wherein the compound of Formula II is a compound of Formula IV:



or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, or solvate that is effective in the treatment or prevention of a condition selected from the group consisting of obesity and the metabolic syndrome thereof in a mammal including a human.

6. The use of claim 4, wherein the compound of Formula III is a compound of Formula V:




or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, or solvate that is effective in the treatment or prevention of a condition selected from the group consisting of obesity and the metabolic syndrome thereof in a mammal including a human.

7. Use of (a) a therapeutically effective amount of a pharmaceutical composition, and (b) a pharmaceutically acceptable excipient, carrier, or diluent in the manufacture of a medicament for the treatment of a condition selected from the

group consisting of obesity and the metabolic syndrome in a mammal including a human, wherein the medicament is to be administered to a mammalian subject in need thereof,

the pharmaceutical composition comprises a compound of Formula (X):



or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt,

or solvate that is effective in the treatment or prevention of a condition

selected from the group consisting of obesity and the metabolic

syndrome in a mammal including a human, and

wherein the symbols have the following meanings and are, for each occurrence,

independently selected:

Y, Z and A are each independently a carbon;

Q-2 is heterocycle containing at least one heteroatom selected from N, O and S, or aryl;

Q-1 is aromatic ring containing at least one heteroatom selected from N, O and S or phenyl;

R₁ is hydrogen;

R₃ is hydrogen;

R₅, R₆, and R₇ are each independently hydrogen;

R₂', R₂'', R₂''' and R₂'''' are each independently absent, hydrogen, halogen, cyano, nitro,

trihalomethyl, OCF₃, alkyl or substituted alkyl, heterocycle containing at least one

heteroatom selected from N, O and S, or substituted heterocycle containing at least one

heteroatom selected from N, O and S, or OR_a, NR_bR_c, C(=O)OR_e, C(=O)R_a,

C(=O)NR_bR_c, OC(=O)R_a, or NR_bC(=O)R_a,

R_{4'}, R_{4''} and R_{4'''} are each independently hydrogen, halogen, cyano, nitro, CF₃, OCF₃, alkyl or substituted alkyl, OR_a, SR_a, C(=O)R_a, C(=O)OR_a, NH₂, S(O)₂NH₂, NR_bR_c, heterocycle containing at least one heteroatom selected from N, O and S, or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl;

R_a is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S, or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl;

R_b and R_c are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S, or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl, or said R_b and R_c together with the N to which they are bonded optionally form a heterocycle containing at least one heteroatom selected from N, O and S or substituted heterocycle containing at least one heteroatom selected from N, O and S; and

R_e is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle containing at least one heteroatom selected from N, O and S or substituted heterocycle containing at least one heteroatom selected from N, O and S, or aryl or substituted aryl.

8. The use of claims 1 or 7, wherein Q-1 is selected from the group consisting of phenyl, pyrrole, furan, thiophene, pyridine, pyrimidine, pyrazine, pyridazine, imidazole, indole, pyrrolopyridinone, pyridone, pyrrolidine, piridinone, piperidine, and pyrroloazepinone;

wherein one of R_{2'}, R_{2''}, R_{2'''}, and R_{2''''} is C(=O)NR_bR_c,

and wherein

R_b is hydrogen, and

R_c is alkyl substituted with NR_{bn}R_{cn}; wherein R_{bn} and R_{cn} are alkyl, or said R_{bn} and R_{cn} together with the N to which they are bonded optionally form a substituted

heterocycle containing at least one heteroatom selected from N, O and S; wherein said heterocycle is piperidine, or morpholine; or


R_b and R_c together with the N to which they are bonded optionally form a substituted heterocycle containing at least one heteroatom selected from N, O and S; wherein said heterocycle is piperidine, or morpholine; and


two of R_{2'}, R_{2''}, R_{2'''}, and R_{2''''} are independently alkyl, and the other is hydrogen.

9. The use of claims 1 or 7, wherein Q-2 is selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, triazole, thiadiazole, oxadiazole, pyrrolidine, piperidine, azepane, tetrahydrofuran, oxane, oxepane, indole, indolinone, indazole, benzothiazole, quinoline, quinazoline, quinoxaline, imidazopyridine, imidazopyridazine, pyrazolopyridine, pyrazolopyrimidine, phthalazinone, and phenyl;


R_{5'} or R_{4'} is pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuranyl, oxanyl, oxepanyl, pyranyl, phenyl, thiophenyl, pyrazinyl, pyrimidinyl, pyridazinyl, or pyridyl; said piperidinyl, pyranyl, phenyl, thiophenyl, pyrazinyl, pyrimidinyl, pyridazinyl, and pyridyl are optionally substituted with halogen, cyano, nitro, alkyl, OR_a, NR_bR_c, C(=O)OR_e, C(=O)R_a, or C(=O)NR_bR_c; wherein R_a is hydrogen, or alkyl or substituted alkyl, R_b and R_c are independently hydrogen, or alkyl or substituted alkyl, and R_e is alkyl or substituted alkyl; said substituted alkyl is optionally substituted with one or more substituent(s) selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxy carbonyl, aminocarbonyl, aryl, cycloalkyl, and heterocycle containing at least one heteroatom selected from N, O and S; and wherein R_{5''} and R_{5'''} or R_{4''} and R_{4'''} are independently hydrogen, or alkyl or substituted alkyl; said substituted alkyl is optionally substituted with one or more substituent(s) selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxy carbonyl, aminocarbonyl, aryl, cycloalkyl, and heterocycle containing at least one heteroatom selected from N, O and S.

10. Use of (a) a therapeutically effective amount of a pharmaceutical composition, and (b) a pharmaceutically acceptable excipient, carrier, or diluent in the manufacture of a medicament for the treatment of a condition selected from the group consisting of obesity and the metabolic syndrome in a mammal including a human, wherein the medicament is to be administered to a mammalian subject in need thereof, the pharmaceutical composition comprises a compound selected from the group consisting of:








,




,




,




,



,



,




or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, or solvate thereof.


11. The use of any of Claims 1-10, further comprising administering an additional agent selected from the group consisting of: an insulin sensitizing medication, a diabetes medication, a therapeutic for the metabolic syndromes, and a weight-loss medication.

12. The use of any of Claims 1-10, wherein the medicament is further for the treatment of comorbidities closely associated with obesity, wherein the comorbidities include type II diabetes.


13. Use of (a) a therapeutically effective amount of a pharmaceutical composition, and (b) a pharmaceutically acceptable excipient, carrier, or diluent in the manufacture of a medicament for the treatment of reducing or ameliorating morbidity or mortality including at least a symptom or indication known to be associated with obesity and the metabolic syndrome in a mammal including a human, wherein the medicament is to be administered to a mammalian subject in need thereof,

the pharmaceutical composition selected from the group consisting of:







,




,




,




,




,



,






and an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, or solvate thereof; and

wherein morbidity or mortality including at least a symptom or indication known to be associated with obesity and the metabolic syndrome is selected from the group consisting of: excessive weight, excessive fat, a BMI ≥ 25 kg/m², insulin resistance, frequent urination, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, and low high-density lipoprotein (HDL) levels.

14. The use of Claim 13, wherein the morbidity or mortality including at least a symptom or indication known to be associated with obesity and the metabolic syndrome is a BMI ≥ 30 kg/m².

15. A compound selected from the group consisting of:



and a pharmaceutically acceptable salt thereof.

16. The compound of Claim 15 wherein at least one of the hydrogens is a deuterium.